Study of Atomoxetine in Children With ADHD to Assess Symptomatic and Functional Outcomes

Lilly

Status and phase

Completed

Phase 4

Conditions

Attention-Deficit/Hyperactivity Disorder

Treatments

Drug: Atomoxetine

Study type

Interventional

Funder types

Industry

Identifiers

NCT00191633

B4Z-CA-S012

9684

Details and patient eligibility

About

The purpose of this study is to assess whether changes in the symptoms of ADHD show a relationship with changes in functioning in children with ADHD treated with atomoxetine over a 3-month period.

Sex

All

Ages

6 to 11 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients must have ADHD, be outpatients, who are at least 6 years of age and not more than 11 years 8 months of age at Visit 1 so that all testing will be completed before the child reaches age 12.
Patients must have moderately severe symptoms of ADHD.
Patients must be able to swallow study drug capsules.

Exclusion criteria

Patients must not have Bipolar disorder, psychosis, autism, Asperger's syndrome, pervasive developmental disorder, or seizure disorder.
Patients must not have taken atomoxetine prior to starting the study.